Financials
Financial year 2025
AMBIXX from Brecht, company number BE0651692322, closed financial year 2025 with a result of € -195,005 after tax. For that financial year AMBIXX recorded a gross margin of € -62,029 and equity of € 4 million. Compared with financial year 2024, the result moved from € 535,946 to € -195,005. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.
€ 4 million
▼ 5% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -195,005
▼ still € 535,946 profit in 2024
Profit after tax over the fiscal year.
€ 19,727
▼ 52% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 624,149.
People and assets in 2025
€ 1,630
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 369,781
▼ 18% vs 2024
€ 98,010 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 7,537
▼ 96% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 147
▼ € 63,066 vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 436,110 | € 261,407 | € 64,552 | € -62,029 | ▼ € 126,580 |
| Profit after taxes | € 377,195 | € 160,830 | € 535,946 | € -195,005 | ▼ € 730,951 |
| Equity | € 214,378 | € 375,208 | € 4,153,154 | € 3,958,149 | ▼ 5% |
| Total debts | € 928,823 | € 972,715 | € 768,579 | € 466,314 | ▼ 39% |
| Cash | € 52,999 | € 2,496 | € 41,420 | € 19,727 | ▼ 52% |
| Retained profit | € 122,378 | € 283,208 | € 819,154 | € 624,149 | ▼ 24% |
| Bank debt | € 632,700 | € 593,000 | € 448,312 | € 369,781 | ▼ 18% |
| Balance sheet total | € 1,143,202 | € 1,347,923 | € 4,921,733 | € 4,424,463 | ▼ 10% |
Key figures of AMBIXX, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to AMBIXX?
What happened at AMBIXX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 195,005 (▼ € 730,951 vs 2024). filed late Source: NBB ↗
- New establishment in Brecht. KBO
- Start of the company according to the CBE. KBO
In short
From € 377,195 profit in 2022 to € 195,005 loss in 2025.
Paid € 30,237 in corporate taxes since 2022.
Best year ever: 2024, with € 535,946 profit.
A new publication or filing at AMBIXX? We notify you, reason included.
Follow AMBIXXDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind AMBIXX are Marleen Slaets and Laurent Cooreman. It owns 100% of E-pharma, 100% of Pharma United and 66% of Medisynall itself.
Directors
According to the 2025 annual accounts
Marleen Slaets
Director
Also active at: Apotheek De Voogt, APOTHEEK ZWAANTJE, PHARMA UNITED, MEDISYNALL, E-pharma, Idealpharma, Apotheek Cauwenbergh
Establishments
Establishment units
Physical locations of this company
Kapelstraat 15
2960 Brecht
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0651.692.322
- VAT number
- BE 0651.692.322
- Registered office
- Kapelstraat 15, 2960 Brecht
- Names & denominations
- AMBIXX
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 7 April 2016
- Peppol
- Active · Active since 17 Dec 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Mediarepresentatie